News

Filter

EXPERT VIEW: Fewer ‘pay-for-delay’ agreements are likely but they might not disappear altogether

EXPERT VIEW: Fewer ‘pay-for-delay’ agreements are likely but they might not disappear altogether

01-08-2014

The pharmaceutical sector is still reeling from the latest fines imposed by the European Competition…

EuropeEuropean Competition CommissionGenericsInterviewsLegalLupinMylan LaboratoriesPharmaceuticalRegulationServierTeva Pharmaceutical IndustriesUSA

EMA/CHMP positive opinion for Teva’s Seasonique contraceptive

EMA/CHMP positive opinion for Teva’s Seasonique contraceptive

04-07-2014

The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has issued a positive…

EuropePharmaceuticalRegulationReproductiveSeasoniqueTeva Pharmaceutical IndustriesWomen's Health

Teva and Active Biotech will continue with Nerventra development despite negative CHMP decision

25-05-2014

Teva Pharmaceutical Industries, the world’s largest generic drugs firm, and Swedish partner Active…

Active BiotechEuropeNerventraNeurologicalPharmaceuticalRegulationTeva Pharmaceutical Industries

EU approval for Teva’s DuoResp Spiromax for asthma and COPD

EU approval for Teva’s DuoResp Spiromax for asthma and COPD

30-04-2014

The European Commission has granted marketing authorization for Israel-based Teva Pharmaceutical Industries’…

DuoResp SpiromaxEuropeGenericsRegulationRespiratory and PulmonaryTeva Pharmaceutical Industries

EMA/CHMP January meeting highlights

EMA/CHMP January meeting highlights

24-01-2014

There were a number of positive, and negative, opinions issued on January 24, following the monthly meeting…

AB ScienceAdempasBayerBemfolaDainippon Sumitomo PharmaEuropeFinox BiotechHemoprostolLatudaLinepharmaMasivieraNerventraNovartisPTC TherapeuticsReasanzRegulationTakeda PharmaceuticalsTeva Pharmaceutical IndustriesTranslarna

Back to top